ImmunityBio stated that the application includes additional information requested by the FDA to support its supplemental BLA for papillary disease.
ImmunityBio Inc. (IBRX) on Monday announced that it has resubmitted the supplemental biologics license application (BLA) to the U.S. Food and Drug Administration for Anktiva.
Add Asianet Newsable as a Preferred Source
ImmunityBio stated that the application includes additional information requested by the FDA to support its supplemental BLA for papillary disease.
ImmunityBio shares were down more than 5% in Monday’s pre-market trade. Retail sentiment on Stocktwits around the company trended in the ‘bearish’ territory at the time of writing.
Get updates to this developing story directly on Stocktwits.<
For updates and corrections, email newsroom[at]stocktwits[dot]com.<
